Sat­suma's nasal mi­graine can­di­date re­ject­ed by FDA over CMC is­sues 

Sat­suma Phar­ma­ceu­ti­cals was hand­ed a com­plete re­sponse let­ter for its nasal mi­graine drug af­ter the agency found is­sues with the prod­uct’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.